EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions

Kyriazoula Chatzianagnostou, Melania Gaggini iD, Adrian Suman Florentin, Ludovica Simonini, Cristina Vassalle iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25116218 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kyriazoula Chatzianagnostou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione CNR-Regione Toscana G Monasterio, Via G. Moruzzi 1, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although good glycemic control in patients with type 2 diabetes (T2D) can prevent cardiovascular complications, many diabetic patients still have poor optimal control. A new class of antidiabetic drugs (e.g., glucagon-like peptide-1-GLP-1 receptor agonists, sodium-glucose co-transporters-SGLT2 inhibitors), in addition to the low hypoglycemic effect, exert multiple beneficial effects at a metabolic and cardiovascular level, through mechanisms other than antihyperglycemic agents. This review aims to discuss the effects of these new antidiabetic drugs, highlighting cardiovascular and metabolic benefits, through the description of their action mechanisms as well as available data by preclinical and clinical studies. Moreover, new innovative tools in the T2D field will be described which may help to advance towards a better targeted T2D personalized care in future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHumansAnimalsSodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesGlucagon-Like Peptide 1

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT2 inhibitorsatherosclerosiscardiometabolic conditionstype 2 diabetes mellitus

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Fondazione CNR-Regione Toscana G Monasterio, Via G. Moruzzi 1, 56124 Pisa, Italy.
  • Institute of Clinical Physiology, National Research Council, Via G. Moruzzi 1, 56124 Pisa, Italy.
  • Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.

ORCID-Profile: Melania Gaggini, Cristina Vassalle

Zitieren

APA

Chatzianagnostou, K., Gaggini, M., Suman Florentin, A., Simonini, L., & Vassalle, C. (2024). New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116218

Vancouver

Chatzianagnostou K, Gaggini M, Suman Florentin A, Simonini L, Vassalle C. New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116218

BibTeX
@article{Chatzianagnostou2024,
  author = {Chatzianagnostou, Kyriazoula and Gaggini, Melania and Suman Florentin, Adrian and Simonini, Ludovica and Vassalle, Cristina},
  title = {New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25116218}
}
Kostenlos starten →